PF-Atlas › Clinical Trials › NCT03422068

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis . The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

BI 1015550 · Phase 1

Registry ID
NCT03422068
Phase
Phase 1
Status
Completed
Drug / intervention
BI 1015550
Sponsor
Boehringer Ingelheim
Start
2018-03-16
Enrollment
15
Locations
11

About this trial

The primary objective is to investigate safety and tolerability of BI 1015550 in patients with IPF. The secondary objectives are to evaluate the pharmacokinetics (PK) of BI 1015550 in patients with IPF.

View NCT03422068 on ClinicalTrials.gov →

Explore related

All BI 1015550 trialsAll IPF trials

Related trials

BI 1015550 — NCT05321069BI 1015550 — NCT05321082BI 1015550 — NCT06241560
Medical disclaimer. This page summarizes public trial data for NCT03422068 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.